Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cascara sagrada (Rhamnus purshiana) is a traditional Native American laxative containing anthraquinone glycosides that stimulate colon contractions. The bark's compounds cascarosides A and B increase intestinal motility by inhibiting stationary contractions while promoting propulsive movements.
Origin & History
Cascara sagrada is the dried bark of Rhamnus purshiana (Frangula purshiana), a deciduous shrub native to the Pacific Northwest of North America. The bark must be harvested and aged for at least one year or artificially processed through heat or aeration before therapeutic use, as fresh bark contains free anthrones requiring processing for safety.
Research Narrative (Provisional)
The research dossier does not contain specific human clinical trials, randomized controlled trials, or meta-analyses evaluating cascara sagrada's efficacy. The available sources describe traditional use and pharmacological mechanisms but lack the clinical trial data and PMIDs necessary for evidence-based assessment.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Cascara sagrada bark is not consumed as a food source and therefore lacks a conventional macronutrient profile (negligible protein, fat, and carbohydrate contribution at therapeutic doses). The primary bioactive compounds are anthraquinone glycosides (hydroxyanthracene derivatives), comprising approximately 6–9% of dried bark by weight. Key compounds include: • Cascarosides A, B, C, and D (collectively ~60–70% of total anthraquinone content; approximately 4–6% of dried bark), which are C-glycosides of barbaloin and chrysaloin stereoisomers — these are the principal laxative agents. • Emodin (approx. 0.1–0.3% of dried bark), a free aglycone anthraquinone with anti-inflammatory and antimicrobial properties. • Aloe-emodin (trace to ~0.2%), another free anthraquinone aglycone. • Chrysophanol (trace amounts). • Barbaloin/aloin (present as both free and glycosylated forms). • Frangulin and frangula-emodin (minor constituents). The cascarosides are prodrugs — they pass through the small intestine largely intact due to their glycosidic bonds and are hydrolyzed by colonic bacterial β-glucosidases into active aglycones (emodin, aloe-emodin), meaning bioavailability of the active moiety is dependent on gut microbiome composition. Additional non-anthraquinone constituents include: • Tannins (approximately 3–5% of dried bark), contributing astringent properties. • Lipids and resins (minor). • Volatile oils (trace). • Minerals present in trace amounts include calcium, manganese, and potassium, though quantities are negligible at medicinal doses. • Dietary fiber is present in the bark matrix but not nutritionally relevant given typical dose sizes (300–1000 mg dried bark or equivalent extract). Standardized commercial preparations are typically calibrated to contain 20–30 mg hydroxyanthracene derivatives (calculated as cascaroside A) per dose. Aged bark (minimum 1 year or heat-treated) is required to reduce concentrations of free anthrones, which cause griping and nausea. No significant vitamin content has been documented. Bioavailability note: Oral absorption of intact cascarosides in the upper GI tract is minimal (<5%); therapeutic action is almost entirely colon-dependent, requiring microbial metabolism for activation, with peak effect occurring 6–12 hours post-ingestion.
Reported Mechanism (Provisional)
Cascara sagrada's anthraquinone glycosides (cascarosides A and B) are converted by colonic bacteria into active aglycones that stimulate the enteric nervous system. These compounds increase prostaglandin E2 synthesis and enhance chloride secretion, leading to increased water and electrolyte content in the colon. The result is enhanced peristalsis through inhibition of segmental contractions and stimulation of propulsive contractions.
Clinical Narrative (Provisional)
Clinical evidence for cascara sagrada is limited, with most support coming from traditional use rather than controlled trials. Small observational studies suggest laxative effects typically occur within 6-12 hours of administration. The FDA removed cascara sagrada from over-the-counter laxative products in 2002 due to insufficient safety data regarding long-term use and potential carcinogenic effects. Current evidence relies primarily on mechanism studies and historical usage patterns rather than rigorous clinical trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.